Compugen Ltd. CGEN

NAS: CGEN | ISIN: IL0010852080   1/05/2025
1,520 USD (-5,00%)
(-5,00%)   1/05/2025

26 maart 2025 · Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 · Persbericht

4 maart 2025 · /C O R R E C T I O N -- Compugen Ltd./ · Persbericht

4 maart 2025 · Compugen Reports Fourth Quarter and Full Year 2024 Results · Persbericht

3 maart 2025 · Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference · Persbericht

9 september 2024 · Compugen to Present at Single Cell Genomics 2024 Conference · Persbericht

29 augustus 2024 · Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

6 augustus 2024 · Compugen Reports Second Quarter 2024 Results · Persbericht

29 juli 2024 · Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors · Persbericht

23 juli 2024 · Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 · Persbericht

17 juni 2024 · Compugen to Present at Upcoming Antibody Industrial Symposium · Persbericht

30 mei 2024 · Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig · Persbericht

20 mei 2024 · Compugen Reports First Quarter 2024 Results · Persbericht

16 mei 2024 · Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential · Persbericht

15 mei 2024 · Compugen Appoints David Silberman as Chief Financial Officer · Persbericht

6 mei 2024 · Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 · Persbericht

25 april 2024 · Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 · Persbericht

10 april 2024 · Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 · Persbericht

3 april 2024 · Compugen to Participate in Two Upcoming Investor Conferences · Persbericht

11 maart 2024 · Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy · Persbericht

6 maart 2024 · Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 · Persbericht

Mijn selecties